Skip to Content
Merck
CN
  • Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer.

Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer.

Cancer cell (2021-03-06)
Yang Chen, Jiha Kim, Sujuan Yang, Huamin Wang, Chang-Jiun Wu, Hikaru Sugimoto, Valerie S LeBleu, Raghu Kalluri
ABSTRACT

Stromal desmoplastic reaction in pancreatic ductal adenocarcinoma (PDAC) involves significant accumulation of type I collagen (Col1). However, the precise molecular and mechanistic contribution of Col1 in PDAC progression remains unknown. Activated pancreatic stellate cells/αSMA+ myofibroblasts are major contributors of Col1 in the PDAC stroma. We use a dual-recombinase genetic mouse model of spontaneous PDAC to delete Col1 specifically in myofibroblasts. This results in significant reduction of total stromal Col1 content and accelerates the emergence of PanINs and PDAC, decreasing overall survival. Col1 deletion leads to Cxcl5 upregulation in cancer cells via SOX9. Increase in Cxcl5 is associated with recruitment of myeloid-derived suppressor cells and suppression of CD8+ T cells, which can be attenuated with combined targeting of CXCR2 and CCR2 to restrain accelerated PDAC progression in the setting of stromal Col1 deletion. Our results unravel the fundamental role of myofibroblast-derived Co1l in regulating tumor immunity and restraining PDAC progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Collagen, Type I solution from rat tail, BioReagent, suitable for cell culture, sterile-filtered
Roche
Liberase TL Research Grade, lyophilized, suitable for tissue processing, optimum pH 7.4
Sigma-Aldrich
Anti-NG2 Chondroitin Sulfate Proteoglycan Antibody, Chemicon®, from rabbit
Roche
DNase I, grade II, from bovine pancreas